Search clinical trials for: Locally Advanced, Unresectable NSCLC, Carcinoma, NSCLC

Total 9337 results

AstraZeneca

Recruiting

CRT( Chemo-Radiation Therapy) Patterns and Short-term Outcomes on Unresectable NSCLC in Routine Practices in Russia (PASSAT)

Unresectable /Inoperable Locally Advanced (Stage II-III) Non-small Cells Lung Cancer (NSCLC)

Russian Federation
H. Lee Moffitt Cancer Center and Research Institute

Recruiting

Genomically Guided Radiation Dose Personalization in Locally Advanced NSCLC

Nonsmall Cell Lung Cancer | Nonsmall Cell Lung Cancer Stage III | Unresectable Non-Small Cell Lung Carcinoma | Nonsmall Cell Lung Cancer, Stage II

United States
Parc de Salut Mar
GUARDANT HEALTH

Recruiting

Molecular Profiling and Dynamic Changes of ctDNA in Unresectable Locally Advanced NSCLC

Lung Cancer | Stage III Lung Cancer | Unresectable Lung Carcinoma

Spain
Biomea Fusion Inc.

Recruiting

Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer

Colorectal Cancer | Pancreatic Cancer | NSCLC | Non Small Cell Lung Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | CRC | KRAS Mutation-Related Tumors | Relapsed Cancer | Refractory Cancer | Stage IV Non-small Cell Lung Cancer | Stage IV Colorectal Cancer | Stage III Non-small Cell Lung Cancer | Stage III NSCLC and other conditions

United States, Korea, Republic of
AstraZeneca

Recruiting

A Multi-center, Non-interventional, Prospective Study of Durvalumab in Unresectable Locally Advanced NSCLC in Routine Clinical Practice in Russia (NIS durvalumab)

NSCLC, Non-small-cell Lung Carcinoma

Russian Federation
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

Study of HS-10241 in Combination With Almonertinib in Patients With Locally Advanced or Metastatic NSCLC

Non Small Cell Lung Cancer

China
Jinming Yu

Recruiting

WX-0593 Combined With Concurrent Chemoradiotherapy in Unresectable Locally Advanced NSCLC

Non-small Cell Lung Cancer (NSCLC)

China
Sung Yong Lee
Yuhan Corporation

Recruiting

A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation Therapy (PLATINUM)

Non-small Cell Lung Cancer Stage III | Non-squamous Non-small-cell Lung Cancer | EGFR Positive Non-small Cell Lung Cancer

Korea, Republic of
Aulos Bioscience, Inc.

Recruiting

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Metastatic Cancer | Advanced Solid Tumor

Australia, United States
AstraZeneca

Recruiting

A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer (PACIFIC-9)

Non-Small Cell Lung Cancer

China, Australia, Korea, Republic of, Canada, Poland, Spain, Vietnam, Germany, Brazil, Italy, Japan, Taiwan, Thailand, United States, United Kingdom, Portugal, Turkey, France, Peru, Colombia, Russian Federation, Ukraine
AstraZeneca
Arcus Biosciences, Inc.

Recruiting

A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC (PACIFIC-8)

Non-Small Cell Lung Cancer

Korea, Republic of, Philippines, United States, Belgium, Hungary, India, Norway, United Kingdom, France, Canada, Germany, Japan, Malaysia, Taiwan, Greece, Italy, Mexico, Turkey, South Africa, Chile, Brazil, Spain, Switzerland, Poland, R... and more
Hoffmann-La Roche

Recruiting

A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer

United States, Korea, Republic of, Belgium, Canada, Australia, Brazil, China, Japan, Taiwan, Israel, France, Singapore, Germany, Spain, Thailand, Italy, Sweden, Turkey, Colombia, Costa Rica, Hong Kong, Poland, Chile, United Kingdom, New... and more
AstraZeneca
Daiichi Sankyo

Recruiting

A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations

Locally Advanced or Metastatic Non-Small Cell Lung Cancer

China, Korea, Republic of, Germany, Italy, Poland, Belgium, Mexico, Turkey, Spain, France, United States, Canada, Taiwan, Brazil, Austria, Hong Kong, India, Japan, Netherlands, Denmark
Takeda

Recruiting

A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer

Colorectal Cancer | Non-small Cell Lung Cancer (NSCLC) | Squamous Cell Cancer of Head and Neck (SCCHN)

Korea, Republic of, United States, Australia
BeiGene

Recruiting

A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer

NSCLC | Non-small Cell Lung Cancer

Japan, United States, France, Mexico, Germany, Argentina, Brazil, Korea, Republic of, Turkey
AstraZeneca
Daiichi Sankyo

Recruiting

Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC (DL03)

Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Korea, Republic of, Italy, Poland, Malaysia, Taiwan, Thailand, United States, France, Netherlands, Philippines, Canada, Singapore, Spain, Turkey, Australia, Belgium, Israel
Daiichi Sankyo
Merck Sharp & Dohme LLC; AstraZeneca

Recruiting

HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer (NSCLC)

United States, Korea, Republic of, Taiwan, Japan
National Cancer Institute (NCI)
NRG Oncology

Recruiting

Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), The ARCHON-1 Trial

Stage III Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Unresectable Lung Non-Small Cell Carcinoma | Locally Advanced Lung Non-Small Cell Carcinoma | Locally Recurrent Lung Non-Small Cell Carcinoma

United States
AstraZeneca

Active, not recruiting

Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer

Non-Small Cell Lung Cancer

Poland, India, Thailand, Vietnam, Turkey, Korea, Republic of, Brazil, Czechia, Hungary, Japan, Mexico, Peru, Philippines, Russian Federation
Hoffmann-La Roche

Active, not recruiting

A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) (SKYSCRAPER-03)

Non-small Cell Lung Cancer (NSCLC)

United States, Korea, Republic of, United Kingdom, Australia, Belgium, Brazil, Canada, China, Portugal, Spain, France, Germany, Poland, Hong Kong, Israel, Thailand, Turkey, Japan, Austria, Hungary, Italy, Taiwan, Netherlands, Greece, New... and more
BeiGene

Active, not recruiting

Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer

Nonsmall Cell Lung Cancer, Stage IV | Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC)

United States, China, Korea, Republic of, France, Spain, Australia, Austria
AstraZeneca

Completed

Study to Access Safety of Durvalumab in Indian Adult Patients With Locally Advanced NSCLC

Unresectable Non-small Cell Lung Cancer (NSCLC)

India
Symphogen A/S

Active, not recruiting

Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies

Solid Tumor | Metastatic Cancer

United States, Canada
TheraOp
AstraZeneca

Active, not recruiting

PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC (PACCELIO)

Stage III Non-small Cell Lung Cancer | Locally Advanced | Unresectable

Switzerland
Fudan University

Terminated

Tislelizumab Combined With Sitravatinib as Consolidation Treatment Following Concurrent Chemoradiation in Patients With Locally Advanced, Unresectable NSCLC

Non-small Cell Lung Cancer

China
MedImmune LLC

Completed

Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC (COAST)

Stage III Non-small Cell Lung Cancer | Unresectable

United States, Canada, Italy, Spain, France, Hong Kong, Portugal, Taiwan, Poland
Amgen

No longer available

Expanded Access of Sotorasib

Non Small-cell Lung Cancer | Locally Advanced Unresectable NSCLC | Locally Advanced Metastatic NSCLC

United States, Taiwan, Israel, Saudi Arabia, Brazil, Argentina
Zhejiang Genfleet Therapeutics Co., Ltd.

Active, not recruiting

A Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLC

NSCLC, Stage III

China
WindMIL Therapeutics
Bristol-Myers Squibb

Terminated

Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC

NSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer Metastatic

United States
Chugai Pharmaceutical
Japan Lung Cancer Society

Completed

A Study of Atezolizumab in Patients With Unresectable, Locally Advanced or Metastatic NSCLC (J-TAIL)

Non-small-Cell Lung Cancer

Japan
Radiotherapy Oncology Centre "Santa Maria" Hospital
Paola Anselmo,MD; Michelina Casale,PhD; Ernesto Maranzano,MD; Fabio Trippa,MD

Completed

Stereotactic Ablative Radiotherapy in Locally Advanced Non Small Cell Lung Cancer (START-NEW-ERA)

Locally Advanced Lung Non-Small Cell Carcinoma

Italy
iOMEDICO AG
Bristol-Myers Squibb

Completed

Nab-Paclitaxel in Combination With Carboplatin as First-line Therapy in Patients With NSCLC (NEPTUN)

Carcinoma, Non-Small-Cell Lung

Germany
Array Biopharma, now a wholly owned subsidiary...

Withdrawn

Efficacy and Safety of LGX818 in Patients With Advanced or Metastatic BRAF V600 Mutant NSCLC

Non-Small Cell Lung Cancer

United States
Clovis Oncology, Inc.

Terminated

Multicenter Study of Rociletinib Administered to Patients With Previously Treated Mutant EGFR Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

United States, Korea, Republic of, Germany, Taiwan, Australia, Hong Kong, Netherlands, Spain, France, United Kingdom, Canada, Switzerland
Clovis Oncology, Inc.

Terminated

Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients

Locally Advanced or Metastatic Non Small Cell Lung Cancer

United States, Australia, France, Poland
Celgene
BeiGene

Terminated

A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer (RATIONALE001)

Carcinoma, Non-Small-Cell Lung

Spain, United States, Japan, China, Canada, United Kingdom, Belgium, Singapore, Korea, Republic of, Netherlands, France, Romania, Greece, Germany, Taiwan, Finland, Italy, Poland, Hungary, Ireland, Portugal, New Zealand, Russian Federation
Cancer Institute and Hospital, Chinese Academy...

Unknown

Real-world Treatment Patterns and Clinical Outcomes in EGFR-mutant Unresectable Locally Advanced NSCLC

Non Small Cell Lung Cancer | Stage III Non-small-cell Lung Cancer | EGFR Mutation-Related Tumors
Clovis Oncology, Inc.

Terminated

TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy

Non-small Cell Lung Cancer

Korea, Republic of, United States, France, Germany, Netherlands, Australia, Spain, Taiwan, United Kingdom, Italy
Clovis Oncology, Inc.

Terminated

TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR-mutant/Metastatic NSCLC Who Have Not Had Any Previous EGFR Directed Therapy (EGFR)

Non-Small Cell Lung Cancer

Korea, Republic of, United States, Spain, Hong Kong, Taiwan, Germany, Italy
Shandong Cancer Hospital and Institute

Unknown

Consolidation Sintilimab After Concurrent Chemoradiation in Patients With Unresectable Stage III NSCLC (CONSIST)

Carcinoma, Non-Small Cell Lung

China
Charite University, Berlin, Germany

Completed

InductionChemo-Radio-Antibody-Treatment (ICRAT)

Squamous Cell Carcinoma of the Neck | Squamous Cell Carcinoma of the Head

Germany
Shionogi

Completed

Study of S-3304 in Patients With Locally Advanced Non-Small Cell Lung Cancer

Lung Cancer | Non Small Cell Lung Cancer | Stage IIIA Non Small Cell Lung Cancer | Stage IIIB Non Small Cell Lung Cancer

United States
AstraZeneca

Completed

Europe-Japan Diagnostic Study for EGFR Testing (ASSESS)

EGFR Mutation Status in aNSCLC Patients (Locally Advanced and/or Metastatic Disease) With Adenocarcinoma and Non-adenocarcinoma Histologies.

Italy, Spain, United Kingdom, Sweden, Japan, Netherlands, Germany, France
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb

Completed

Cetuximab Plus Conformal Thoracic Radiotherapy in Patients (Pts) With Inoperable or Unresectable Locally Advanced Non-Small Cell Lung Cancer (LA - NSCLC)

Lung Cancer

United States
Mt. Sinai Medical Center, Miami
Amgen

Completed

Combined Modality Therapy With Growth Factor Support in Locally Advanced Non-small Cell Lung Cancer (NSCLC)

Unresectable Locally Advanced NSCLC

United States
Cancer Institute and Hospital, Chinese Academy...

Unknown

Cisplatin/Etoposide and Concurrent Radiotherapy With or Without Celecoxib in Patients With Unresectable Locally Advanced Non-small Cell Lung Cancer (NSCLC)

Lung Cancer

China
University Hospital, Antwerp
Eli Lilly and Company; Universiteit Antwerpen

Completed

Evaluation of Pemetrexed Combined With Cisplatin and Radiotherapy for Unresectable Locally Advanced Non-Small Cell Lung Cancer (NSCLC) (PACCORA)

Non-Small Cell Lung Cancer

Belgium
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Not yet recruiting

Study of Avelumab and Tuvusertib in Participants With Advanced Urothelial Cancer That Has Progressed on Prior Anti-PD-(L)1 Therapy (JAVELIN DDRiver Bladder)

Urothelial Carcinoma

United States, Germany
Hebei Medical University Fourth Hospital

Not yet recruiting

Adebrelimab Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC)

Esophageal Squamous Cell Carcinoma
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

Study of IBI3005 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors

Solid Tumors

Australia

Search clinical trials for: Locally Advanced, Unresectable NSCLC, Carcinoma, NSCLC

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Albania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations